ZyVersa Therapeutics, Inc. (ZVSA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Weston, FL, United States. The current CEO is Stephen C. Glover.
ZVSA has IPO date of 2022-02-11, 7 full-time employees, listed on the Other OTC, a market capitalization of $1.55M.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
